PhD in Development of CAIX-targeting Radioligands to Improve Tumor Retention Belgian Nuclear Research Centre in Belgium

This funded PhD position at the Belgian Nuclear Research Centre (SCK CEN) offers an exciting opportunity to contribute to the advancement of precision oncology through the development of CAIX-targeting radioligands. The project is rooted in organic chemistry and focuses on the synthesis and molecular design of small molecules that selectively bind to carbonic anhydrase IX (CAIX), a protein highly expressed in hypoxic tumors and largely absent from healthy tissues. By leveraging molecular modeling, the successful candidate will design and synthesize a library of CAIX-binding ligands, optimize their structures for enhanced selectivity and tumor retention, and conjugate the most promising candidates to chelators for radiolabeling with therapeutic isotopes such as ¹⁷⁷Lu and ¹⁶¹Tb.

Theranostics, which integrates diagnostic and therapeutic capabilities into a single molecular platform, is rapidly transforming cancer treatment. Compounds like [¹⁷⁷Lu]Lu-DOTATATE and [¹⁷⁷Lu]Lu-PSMA-617 have demonstrated the potential of targeted radionuclide therapy, but new ligand scaffolds are needed to expand the reach of this technology to a broader range of cancer types. This PhD project is chemistry-driven and offers the chance to apply advanced organic synthesis and molecular design skills to the development of next-generation radiotheranostics.

As a PhD researcher at SCK CEN, you will benefit from a multidisciplinary research environment, close cooperation with the academic sector, and access to innovative facilities specifically designed for nuclear experiments. The SCK CEN Academy provides excellent internal training courses, and you will work alongside experienced experts in the field. The position is based in Mol, Antwerp, Belgium, and is fully funded for four years. While specific details on stipend and tuition are not provided, funding is confirmed and includes access to research facilities and training opportunities.

Eligibility requires a Master of Science degree or equivalent in Chemistry, with proven skills in organic synthesis and a strong background in molecular design. Excellent proficiency in English is essential. The application deadline is March 31, 2026, and the position is expected to start on October 1, 2026. For further details and to apply, visit the SCK CEN website or contact [email protected].

This opportunity is ideal for candidates passionate about organic chemistry, molecular modeling, and the development of innovative cancer therapies. The project promises a stimulating research environment and the chance to make a significant impact in the field of radiotheranostics.